Expanded Access

Expanded Access / Compassionate Use Policy

At Aprea, we are committed to the discovery and development of novel anti-cancer compounds that reactivate the tumor suppressor protein, p53. The goal of our development program is to expeditiously bring our investigational therapies to markets, so as to potentially provide benefit for the greatest number of patients. We believe that focusing on our clinical trials is the most appropriate way to achieve this goal. Therefore, at this time, we do not offer access to APR-246 outside of our clinical trials and we do not have any Expanded Access or Compassionate Use programs.

We are conducting clinical trials to obtain clinical data required for submission, review and approval by regulatory authorities of marketing applications for our investigational therapies. In this regard, we welcome patients seeking to participate in our trials. To obtain further information regarding our clinical trials and potential opportunities to participate, please see details posted on ClinicalTrials.gov. A link to APR-246 clinical trials is below:


For all inquiries relating to APR-246, please contact: info@aprea.com

Consistent with the 21st Century Cures Act, Aprea may revise this Expanded Access policy at any time. This policy applies to all of Aprea’s investigational products.